Neurocrine Biosciences
NBIX
232 hedge funds and large institutions have $3.86B invested in Neurocrine Biosciences in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 66 increasing their positions, 97 reducing their positions, and 22 closing their positions.
496% more call options, than puts
Call options by funds: $82.9M | Put options by funds: $13.9M
91% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 22
11% more capital invested
Capital invested by funds: $3.47B → $3.86B (+$389M)
9% more funds holding
Funds holding: 213 → 232 (+19)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
32% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 97
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$44.1M |
| 2 |
SIG
Senator Investment Group
New York
|
+$39.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$34M |
| 4 |
JP Morgan Chase
New York
|
+$27.2M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$85.6M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$58.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$40.4M |
| 4 |
O
OrbiMed
New York
|
-$38.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$35.9M |
NBIX Hedge Fund Activity: Q2 2016 in Review
232 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2016, worth a combined $3.86B — up 11% from $3.47B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new NBIX positions and 22 closed out — a net gain of 20 holders — while 66 added to existing stakes and 97 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $44.1M. The largest seller was Visium Asset Management, cutting an estimated $85.6M.
- 232 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2016, up from 213 in Q1 2016.
- Funds reported $3.86B of Neurocrine Biosciences stock for Q2 2016, up 11% quarter-over-quarter.
- 42 funds opened new Neurocrine Biosciences positions in Q2 2016 and 22 closed out, a net change of +20 holders.
- The largest Neurocrine Biosciences buyer in Q2 2016 was AllianceBernstein, an estimated $44.1M added.
- The largest Neurocrine Biosciences seller in Q2 2016 was Visium Asset Management, an estimated $85.6M sold.
Based on aggregated 13F filings for Q2 2016.